Oncopeptides AB (publ)

Stockholm Stock Exchange ONCO.ST

Oncopeptides AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2023: 126,835,618

Oncopeptides AB (publ) Shares (Diluted, Weighted) is 126,835,618 for the year ending December 31, 2023, a 54.08% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

Oncopeptides AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2022 was 82,320,000, a 9.33% change year over year.
Oncopeptides AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2021 was 75,292,000, a 20.72% change year over year.
Oncopeptides AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2020 was 62,369,000, a 20.63% change year over year.
Oncopeptides AB (publ) Shares (Diluted, Weighted) for the year ending December 31, 2019 was 51,701,000, a 20.43% change year over year.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

Stockholm Stock Exchange: ONCO.ST

Oncopeptides AB (publ)

CEO	Ms. Sofia Heigis M.Sc.
IPO Date	Feb. 22, 2017
Location	Sweden
Headquarters	Vastra Tradgardsgatan 15
Employees	79
Sector	Healthcare
Industries Biotechnology Pharmaceuticals Plastics

Description

Oncopeptides AB (publ), a biotech company, develops pharmaceuticals drugs for the treatment of cancer in the United States, Europe, and internationally. Its lead product candidate is melflufen, an anti-cancer peptide drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.

Key trends

Past 5 years